PRESENT CHALLENGES OF MATHEMATICS IN ONCOLOGY AND BIOLOGY OF CANCER
Description
This workshop aims at bringing together specialists and young researchers from different mathematical backgrounds (modeling, numerical simulations and analysis) and working in the field of oncology. This workshop would follow two previous workshops successfully organized by the CIRM in 2009 and 2011. The interest of bringing closer the world of mathematicians, oncologists and biologists is getting more and more accepted and is a very promising way of setting trans-disciplinary collaborations. Important progresses have been achieved in the discipline of onco-mathematics in the last decade.
The congress will focus on five topics:
Microtubules, migration and cancer
Metronomic chemotherapy
Cancer Stem cells, evolution of phenotype
Biomarkers
Imaging and cancer
Through these sessions, we will put in light how mathematical modeling can help oncologists in terms of prognostic, prediction and therapy scheduling. We want to gather international experts in these five area of research in order to exchange and intensify the relations between the mathematical pharmacologists and oncologists communities.
Organizing commitee
Nicolas André (MCU-PH, Aix-Marseille University, Centre de Recherche en Oncobiologie et Oncopharmacologie, CRO2, INSERM UMR_S 911 and MGHI)
Assia Benabdallah (PR, Aix-Marseille University, Institut de mathématique de Marseille, I2M CNRS, UMR 7373)
- Dominique Barbolosi (PR, Aix-Marseille University, CRO2)
Assia Benabdallah (PR, Aix-Marseille University, I2M)
- Manuel Gonzalez-Burgos (PR, Universidad de Sevilla, Spain)
Florence Hubert (MCF, Aix-Marseille University, I2M)
Scientific commitee
F. Barlesi (PU-PH, Faculty of medecine, Aix-Marseille University, FRANCE)
J. Clairambault (DR, INRIA Rocquencourt, Paris, FRANCE)
E. Grenier (PR, ENS Lyon, FRANCE)
- S. Honoré (MCF-PH, Faculty of pharmacy, Aix-Marseille University, FRANCE)
U. Ledzewicz (Southern Illinois University Edwardsville, USA)
C. Meille (Roche industry, Bale, SWITZERLAND)
.
Reply to this article
discussion